The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Formularies


Psychiatry related information on Formularies


High impact information on Formularies

  • Ethanol in formularies of US teaching hospitals [7].
  • OBJECTIVE: To assess the effect of copayment increases associated with 3-tier formulary adoption on use and spending patterns for ADHD medications for children [8].
  • The formulary restriction limited meperidine to use exclusively for rigors or procedural sedation and was supported by an educational initiative and a computerized order entry system [9].
  • CONCLUSIONS: Three-tier formularies appear to reduce the use of COX-2-selective inhibitors among all patients with arthritis, even those at risk of experiencing gastrointestinal complications from using nonselective NSAIDs [10].
  • Between 1977 and 1985, gentamicin was the only formulary aminoglycoside at the Buffalo Veterans Administration Medical Center. During this time, there was a significant increase in the amount of gentamicin purchased [11].

Chemical compound and disease context of Formularies


Biological context of Formularies


Associations of Formularies with chemical compounds


Gene context of Formularies

  • This analysis suggests that a decision to select filgrastim over sargramostim for formulary inclusion based on the safety profile is not appropriate because currently available data are equivocal and that such decisions would more appropriately be based on efficacy and cost [25].
  • The colony-stimulating factors (CSFs) sargramostim and filgrastim have a broad range of potential indications and represent a costly formulary addition when acquisition price alone is considered; their comparative safety is unclear [25].
  • The effect of converting from simvastatin to atorvastatin on PAI-1 has not been reported and may be an additional consideration when making a formulary medication switch [26].
  • Particularly in light of recent events, the case of the cyclooxygenase-2 inhibitors for the treatment of arthritis yields interesting perspectives into formulary decision making [27].
  • New drugs: which should be included in the formulary? Epilepsy: all new drugs should be included [28].

Analytical, diagnostic and therapeutic context of Formularies


  1. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside. King, J.W., White, M.C., Todd, J.R., Conrad, S.A. Clin. Infect. Dis. (1992) [Pubmed]
  2. Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size. Silberstein, S.D., Dodick, D., Kesslick, J. Headache. (2005) [Pubmed]
  3. The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Jones, R.N. Diagn. Microbiol. Infect. Dis. (1992) [Pubmed]
  4. Limiting the emergence of extended-spectrum Beta-lactamase-producing enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. Lipworth, A.D., Hyle, E.P., Fishman, N.O., Nachamkin, I., Bilker, W.B., Marr, A.M., Larosa, L.A., Kasbekar, N., Lautenbach, E. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America. (2006) [Pubmed]
  5. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. Spearman, M.E., Summers, K., Moore, V., Jacqmin, R., Smith, G., Groshen, S. Clinical therapeutics. (1997) [Pubmed]
  6. Formularies in integrated health systems: Fallon Healthcare System. Cano, S.B. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. (1996) [Pubmed]
  7. Ethanol in formularies of US teaching hospitals. Blondell, R.D., Dodds, H.N., Blondell, M.N., Looney, S.W., Smoger, S.H., Sexton, L.K., Wieland, L.S., Swift, R.M. JAMA (2003) [Pubmed]
  8. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Huskamp, H.A., Deverka, P.A., Epstein, A.M., Epstein, R.S., McGuigan, K.A., Muriel, A.C., Frank, R.G. Arch. Gen. Psychiatry (2005) [Pubmed]
  9. Eliminating analgesic meperidine use with a supported formulary restriction. O'Connor, A.B., Lang, V.J., Quill, T.E. Am. J. Med. (2005) [Pubmed]
  10. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Briesacher, B., Kamal-Bahl, S., Hochberg, M., Orwig, D., Kahler, K.H. Arch. Intern. Med. (2004) [Pubmed]
  11. Gentamicin resistance among gram-negative bacillary blood isolates in a hospital with long-term use of gentamicin. Mylotte, J.M. Arch. Intern. Med. (1987) [Pubmed]
  12. Toward a standard drug formulary for the treatment of headache. Klapper, J.A. Headache. (1995) [Pubmed]
  13. Pharmacy-enforced outpatient drug treatment protocols: a case study of Medi-Cal restrictions for cefaclor. McCombs, J.S., Nichol, M.B. The Annals of pharmacotherapy. (1993) [Pubmed]
  14. Treatment of urinary tract infections in Dutch hospitals. Stobberingh, E., Janknegt, R., Wijnands, W.J. Infection (1996) [Pubmed]
  15. Atazanavir: a new protease inhibitor to treat HIV infection. Musial, B.L., Chojnacki, J.K., Coleman, C.I. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. (2004) [Pubmed]
  16. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Condra, L.J., Morreale, A.P., Stolley, S.N., Marcus, D. The American journal of managed care. (1999) [Pubmed]
  17. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Malinowski, J.M. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. (1998) [Pubmed]
  18. Buspirone: an update on a unique anxiolytic agent. Jann, M.W. Pharmacotherapy (1988) [Pubmed]
  19. Infection control or formulary control: what is the best tool to reduce nosocomial infections due to methicillin-resistant Staphylococcus aureus? Hota, B. Clin. Infect. Dis. (2006) [Pubmed]
  20. Effect of formulary restriction of cefotaxime usage. DeVito, J.M., John, J.F. Arch. Intern. Med. (1985) [Pubmed]
  21. Place of parenteral cephalosporins in the ambulatory setting: clinical evidence. Nathwani, D. Drugs (2000) [Pubmed]
  22. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. Plosker, G.L., Dunn, C.I., Figgitt, D.P. Drugs (2000) [Pubmed]
  23. Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan, T.D. Clinical pharmacokinetics. (1995) [Pubmed]
  24. National survey of stress ulcer prophylaxis. Lam, N.P., Lê, P.D., Crawford, S.Y., Patel, S. Crit. Care Med. (1999) [Pubmed]
  25. Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions. Kellihan, M.J. Clinical therapeutics. (1993) [Pubmed]
  26. The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1. Ito, M.K. Journal of clinical pharmacology. (2001) [Pubmed]
  27. Formulary decision-making considerations: COX-2 inhibitors. Shaya, F.T., Wong, W., Shin, J.Y., Martin, L., Samant, N. Managed care interface. (2004) [Pubmed]
  28. New drugs: which should be included in the formulary? Epilepsy: all new drugs should be included. Pierre-Louis, S.J. Arch. Neurol. (2000) [Pubmed]
  29. Assessing the cost of albuterol inhalers in the Michigan and California Medicaid Programs: a total cost-of-care approach. Tierce, J.C., Meller, W., Berlow, B., Gerth, W.C. Clinical therapeutics. (1989) [Pubmed]
  30. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Coplin, W.M., Rhoney, D.H., Rebuck, J.A., Clements, E.A., Cochran, M.S., O'Neil, B.J. Neurol. Res. (2002) [Pubmed]
  31. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Gaynes, R., Rimland, D., Killum, E., Lowery, H.K., Johnson, T.M., Killgore, G., Tenover, F.C. Clin. Infect. Dis. (2004) [Pubmed]
  32. Hospital pharmacy and emergency department availability of parenteral pyridoxine. Gospe, S.M., Bell, R.M. Pediatric emergency care. (2005) [Pubmed]
WikiGenes - Universities